Literature DB >> 429515

Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation.

M E Quigley, S J Judd, G B Gilliland, S S Yen.   

Abstract

Administration of a dopamine (DA) antagonist, metoclopramide (MCP) resulted in dose-related acute increments of circulating levels of LH and FSH in patients with hyperprolactinemic anovulation due to pituitary microadenoma but not in normal cycling women during the early follicular phase. Concomitant PRL responses to MCP in hyperprolactinemic patients were 1/10 those observed in the cycling women. These findings suggest a relative DA excess at the hypothalamic LRF neurons and a relative DA deficiency at the adenoma lactotroph of hyperprolactinemic patients as compared to cycling women.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429515     DOI: 10.1210/jcem-48-4-718

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Hyperprolactinemia: neuroendocrine and diagnostic aspects.

Authors:  F Camanni; E Ciccarelli; E Ghigo; E E Müller
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

2.  Similarity between the effects of suprachiasmatic nuclei lesions and of pinealectomy on gonadotropin release in ovariectomized, sulpiride-treated and melatonin-replaced rats.

Authors:  D Acuña-Castroviejo; B Fernández; J L Castillo; C M del Aguila
Journal:  Experientia       Date:  1993-09-15

3.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

4.  Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas.

Authors:  F Iannotta; P Fachinetti; A Fachinetti; G Pinotti; L Usellini
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

5.  Trends in the management of prolactinomas.

Authors: 
Journal:  Br Med J       Date:  1980-08-02

Review 6.  New concepts in the regulation of hypothalamic gonadotropin releasing hormone (GnRH) secretion.

Authors:  D D Rasmussen
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

7.  Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; L A Perić
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

8.  Hypothalamic-pituitary-testicular function in men with PRL-secreting tumors.

Authors:  B Ambrosi; M Gaggini; P Travaglini; P Moriondo; R Elli; G Faglia
Journal:  J Endocrinol Invest       Date:  1981 Jul-Sep       Impact factor: 4.256

9.  The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.

Authors:  R W Prescott; D G Johnston; P K Taylor; J Haigh; D R Weightman; K Hall; D B Cook
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

10.  Differential effects of acute DA receptor blockade with domperidone on LH and TSH release in patients with hyperprolactinemia.

Authors:  J R Peters; M D Rodriguez-Arnao; S M Foord; C Edwards; C Dieguez; S Woodhead; R Hall; M F Scanlon
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.